Our Resources | Association for Accessible Medicines

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Mar 11, 2019 | Rachel Schwartz

AAM Statement in Response to Administration's FY 2020 Budget Proposal

Healthcare Leadership Luncheon sponsored by Mylan N.V. and powered by Women in Health Policy (WiHP)

Mar 11, 2019 | Anna McDermott-Vitak

Talking Female Leadership at Access! 2019

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 7, 2019 | Rachel Schwartz

AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements

Mar 5, 2019 | Rachel Schwartz

AAM Statement on Dr. Scott Gottlieb's Departure

AAM Statement on Avalere Report

Feb 28, 2019 | Rachel Schwartz

New Study Shows Seniors Paid Nearly $22 Billion in Extra Out-of-Pocket Costs for Generic Medicines

Feb 26, 2019 | Erica Klinger

Rich’s Generic Story: No Sweat

Jonathan Kimball Joins AAM as Vice President, Trade & International Affairs

Feb 25, 2019 | Rachel Schwartz

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars

Feb 20, 2019 | Craig Burton

HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

Feb 19, 2019 | Rachel Schwartz

Patient Victory: Supreme Court Denies Review of Drug Pricing Law HB 631

AAM President and CEO Chip Davis

Feb 15, 2019 | Rachel Schwartz

Access! New Orleans Style: An Industry Steps Up

AAM Welcomes the Re-introduction of the PACED Act

Feb 13, 2019 | Rachel Schwartz

AAM Welcomes Re-Introduction of the PACED Act

Pass CREATES Act - lower prescription drug prices for patients

Feb 8, 2019 | Rachel Schwartz

Statement from the Association for Accessible Medicines on the Introduction of the CREATES Act